Back to search

Article

Targeting Liver Epsins Ameliorates Dyslipidemia in Atherosclerosis through Inhibition of Proprotein Convertase Subtilisin/Kexin Type 9-Mediated Low-density Lipoprotein Receptor Degradation

2024-08-27

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> The low-density lipoprotein receptor (LDLR) in the liver plays a crucial role in clearing low-density lipoprotein cholesterol (LDL-C) from the bloodstream. This process takes place mainly in the liver. Under atherogenic conditions, Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), secreted by the liver, binds to LDLR on hepatocytes, preventing its recycling and enhancin...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a3417202-beed-540c-86db-316606eec6fc
DOI
10.1101/2024.08.26.609742
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Targeting Liver Epsins Ameliorates Dyslipidemia in Atherosclerosis through Inhibition of Proprotein Convertase Subtilisin/Kexin Type 9-Mediated Low-density Lipoprotein Receptor DegradationDOI 10.1101/2024.08.26.609742
Targeting Epsins by nanotherapy regulates lipid metabolism and promotes ABCG1-mediated cholesterol efflux to fortify atheroma regressionSemantic proximity
Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE−/− miceSemantic proximity
Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.Semantic proximity
Single-Cell Analysis Reveals a Critical Role for Macrophage Epsins in Regulating the Origin of Foam Cells in Atherosclerosis.Semantic proximity
PCSK7: a Novel Regulator of Apolipoprotein B and a Potential Target Against Non-Alcoholic Fatty Liver DiseaseSemantic proximity
Targeting PCSK9 for the treatment of hypercholesterolemia.Semantic proximity
[Progress on the molecular mechanisms of PCSK9-mediated degradation of low density lipoprotein receptor].Semantic proximity
Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.Semantic proximity
Hepatic retromer is essential for systemic cholesterol homeostasis by regulating lysosomal cholesterol metabolismSemantic proximity
Engineered Red Blood Cells Carrying PCSK9 Inhibitors Persistently Lower LDL and Prevent ObesitySemantic proximity
The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.Semantic proximity
Potent Efficacy of Computer-Aided Designed Peptide Degrader Drug on PCSK9-Mediated HypercholesterolemiaSemantic proximity
Select a neighboring publication to make it the new centre.